Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 2221-2230 Newer>

The Motley Fool June 4, 2004 W.D. Crotty	Dueling Fools: Nokia's Ready to Deliver Mobile phone maker Nokia is really a heavyweight poised to outclass its competition. In the meantime, a low stock price provides an excellent opportunity to pick up an outstanding company at a bargain.
The Motley Fool June 4, 2004 Dave Marino-Nachison	Christopher & Banks Sweats It Out The women's apparel retailer plans to keep growing even as same-store sales slump.
The Motley Fool June 4, 2004 Bill Mann	Elizabeth Arden Stops the Clock By decree of the board, Elizabeth Arden's 2004 began on January 31 and will end on June 30, 2004. July 1, according to the fragrance and beauty products company, will be the beginning of 2005.
The Motley Fool June 4, 2004 Tom Taulli	Comverse Trickles Up What's good for the carriers is good for companies like Comverse Technology.
The Motley Fool June 4, 2004 Rich Smith	Symantec's Bizarre Swap After peeling back layers of buybacks, its shareholder dilution is more historic than prospective.
The Motley Fool June 4, 2004 Rick Aristotle Munarriz	Focusing on IPIX Words can lead to dramatic market moves, so watch what you hear! The maker of video surveillance equipment soared just over 50% in one day.
The Motley Fool Brian Gorman	Daimler's Success Story? When DaimlerChrysler recently rolled out U.S. sales data for May, the results for its new Chrysler 300 were remarkable. But the car's success carries the danger of becoming a Pyrrhic victory for the automaker.
BusinessWeek June 14, 2004 Gene G. Marcial	A Bright Gleam On Apex Would you invest in Apex Silver Mines, whose main property, as yet undeveloped, is in far-off Bolivia? Some high-stakes players have taken big chunks.
BusinessWeek June 14, 2004 Gene G. Marcial	As Offices Stock Up, Staples Is Clicking Along Staples, king of office supplies, is the retail stock to own.
BusinessWeek June 14, 2004 Gene G. Marcial	From Pain Therapeutics: A Better Pain Killer Remoxy, now in proof-of-concept trials, could become the replacement for the most popular opioid pain killer OxyContin, with a potential $1 billion market.
<Older 2221-2230 Newer> Return to current articles.